Patterns of p53→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke

Carcinogenesis

Volumn 22, Issue 3, 2001, Pages 367-374

  Hainaut, Pierre ^a   Pfeifer, Gerd P ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CARCINOGEN; CIGARETTE SMOKE; DNA; GUANINE; MUTAGENIC AGENT; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; THYMINE; TOBACCO SMOKE;

ARTICLE; CANCER RESEARCH; CARCINOGEN DNA INTERACTION; CIGARETTE SMOKING; CONTROLLED STUDY; DATA BASE; DNA DAMAGE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION PROCESSING; LIVER CELL CARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MALE; MUTAGENESIS; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE; CASE CONTROL STUDY; CODON; GENETICS; LUNG TUMOR; PLANT; POINT MUTATION; SMOKE; TOBACCO;

CASE-CONTROL STUDIES; CODON; DNA DAMAGE; GUANINE; HUMANS; LUNG NEOPLASMS; MUTAGENS; PLANTS, TOXIC; POINT MUTATION; SMOKE; THYMINE; TOBACCO;

EID: 0034745389     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Smoking and lung cancer: Scientific challenges and opportunities
2. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking
3. Tobacco smoking as a possible etiological factor in bronchiogenic carcinoma. A study of six hundred and eighty-four proved cases
4. Smoking and carcinoma of the lung
5. Smoking and lung cancer: An overview
6. Tobacco smoke carcinogens and lung cancer
7. Smoking and the molecular epidemiology of lung cancer
8. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking
9. Progress in understanding the molecular pathogenesis of human lung cancer
10. p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking
11. Cigarette smoking and p53 mutations in lung cancer and bladder cancer
12. A specific spectrum of p53 mutations in lung cancer from smokers: Review of mutations compiled in the IARC p53 database
13. Molecular epidemiology of human cancer risk: Gene-environment interactions and mutation spectrum in human lung cancer
14. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer
15. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung
16. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus
17. Molecular damage in the bronchial epithelium of current and former smokers
18. Clonal genetic alterations in the lungs of current and former smokers
19. Sequential molecular genetic changes in lung cancer development
20. p53 mutations in human cancers
21. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
22. p53 and human cancer: The first ten thousand mutations
23. Carcinogenic epoxides of benzo(a)pyrene and cyclopenta(cd)pyrene induce base substitutions via specific transversions
24. Sequence specificity of mutations induced by benzo(a)pyrene-7,8-diol-9,10-epoxide at endogenous APRT gene in CHO cells
25. Effect of excision repair by diploid human fibroblasts on the kinds and locations of mutations induced by (±)-7b,8a-dihydroxy-9a,10a-epoxy-7,8,9,10-tetrahydrobenzo[a] pyrene in the coding region of the HPRT gene
26. Dose-dependent differences in the profile of mutations induced by (+)-7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene in the coding region of the hypoxanthine (guanine) phosphoribosyltransferase hamster V-79 cells
27. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G→T mutations in the p53 gene
28. An improved fluorometric assay for dosimetry of benzo(a)pyrene diol- epoxide-DNA adducts in smokers' lung: Comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity
29. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo
30. Comparative synchronous fluorescence spectrophotometry and 32P-postlabeling analysis of PAH-DNA adducts in human lung and the relationship to TP53 mutations
31. Polycyclic aromatic hydrocarbon-DNA adducts in humans: Relevance as biomarkers for exposure and cancer risk
32. Immunoperoxidase detection of polycyclic aromatic hydrocarbon-DNA adducts in mouth floor and buccal mucosa cells of smokers and non-smokers
33. Preferential repair and strand-specific repair of benzo(a)pyrene diol epoxide adducts in the HPRT gene of diploid human fibroblasts
34. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers
35. The relationship between benzo[a]pyrene-induced mutagenesis and carcinogenesis in repair-deficient Cockayne syndrome group B mice
36. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53
37. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons
38. Human lung cancer and p53: The interplay between mutagenesis and selection
39. More to smoking and lung cancer than meets the eye?
40. Analysis of different versions of the IARC p53 database with respect to G→T transversion mutation frequencies and mutation hotspots in lung cancer of smokers and non-smokers
41. Sources of bias in the detection and reporting of p53 mutations in human cancer: Analysis of the IARC p53 mutation database
42. Distribution of p53 and K-ras mutations in human lung cancer tissues
43. p53 mutations in lung cancers from non-smoking atomic-bomb survivors
44. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection
45. Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer
46. Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract
47. Distinct mutational spectrum of the p53 gene in lung cancers from Chinese women in Hong Kong
48. p53 mutations in non-small cell lung carcinomas in Hong Kong
49. p53 mutations in non-small-cell lung cancers occuring in individuals without a past history of active smoking
50. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis
51. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan
52. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer
53. Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus
54. A novel molecular staging protocol for non-small cell lung cancer
55. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women
56. p53 Mutations in lung cancer associated with residential radon exposure
57. The expression of p73 is increased in lung cancer, independent of p53 gene alteration
58. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer
59. p53 mutation spectrum and load: The generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
60. Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland
61. Evidence of anti-benzo[a]pyrene diolepoxide-DNA adduct formation in human colon mucosa
62. Exposure-route-dependent DNA adduct formation by polycyclic aromatic hydrocarbons
63. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer
64. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer
65. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer
66. Cytosine methylation determines hot spots of DNA damage in the human P53 gene
67. Crystal structure of a p53 tumor suppressor-DNA complex: A framework for understanding how mutations inactivate p53
68. Evolutionary conservation and somatic mutation hotspot maps of p53: Correlation with p53 protein structural and functional features
69. The major, N2-dG adduct of (+)-anti-B[a]PDE shows a dramatically different mutagenic specificity (predominantly, G→A) in a 5′-CGT-3′ sequence context
70. CpG transition strand asymmetry and hitch-hiking mutations as measures of tumorigenic selection in shaping the p53 mutation spectrum
71. Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells
72. Hypermutability in carcinogenesis
73. Silent and multiple mutations in p53 and the question of the hypermutability of tumors
74. Polymorphism at codon 213 within the p53 gene